Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Diane Trieu

MOHS-Micrographic Surgery Harvey, LA Medical Doctor

NPI 1376710913 CMS profile 1114240

1525 Lapalco Blvd Ste 20, Harvey, LA 70058

Open in the dashboard

General payments

$15,116

747 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Diane Trieu of Harvey, LA is reported in the CMS Open Payments database as having received $15,116 across 747 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,470 168
2024 General $3,584 148
2023 General $2,316 115
2022 General $2,228 115
2021 General $1,682 90
2020 General $1,142 64
2019 General $695 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Diane Trieu
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Diane Trieu were reported at $3,470. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Diane Trieu MOHS-Micrographic Surgery median Middle half National median
2019 $695 $316 $106–$785 $163
2020 $1,142 $162 $68–$412 $114
2021 $1,682 $243 $87–$654 $132
2022 $2,228 $300 $102–$887 $149
2023 $2,316 $364 $125–$1,010 $160
2024 $3,584 $445 $142–$1,108 $164
2025 $3,470 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,229 136 payments
  2. Genzyme Corporation $1,964 97 payments
  3. Janssen Biotech, Inc. $1,639 61 payments
  4. Lilly USA, LLC $1,150 53 payments
  5. UCB, Inc. $1,115 55 payments
  6. Pfizer Inc. $1,048 50 payments
  7. Regeneron Healthcare Solutions, Inc. $815 35 payments
  8. Amgen Inc. $754 44 payments
  9. Incyte Corporation $496 25 payments
  10. Novartis Pharmaceuticals Corporation $435 22 payments
  11. Other $3,470 169 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,459 737 payments
  2. Education $657 10 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $2,498 104 payments
  2. TREMFYA $1,401 47 payments
  3. SKYRIZI $922 61 payments
  4. EUCRISA $833 43 payments
  5. TALTZ $825 43 payments
  6. Otezla $708 42 payments
  7. RINVOQ $699 32 payments
  8. DUPIXENT Inflammation And Immunology $669 28 payments
  9. Bimzelx $620 29 payments
  10. CIBINQO $594 27 payments
  11. Other $8,016 440 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,937

Median for Dermatology: 534

Drug cost

$1,754,877

Median for Dermatology: $67,151

Branded share of claims

13.9%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Unoready Pen Secukinumab Brand 28 $391,143
Dupixent Pen Dupilumab Brand 74 $276,910
Skyrizi Pen Risankizumab-Rzaa Brand 11 $263,474
Humira(Cf) Pen Adalimumab Brand 23 $251,439
Humira Pen Adalimumab Brand 14 $199,648
Tremfya Guselkumab Brand 11 $153,877
Enbrel Sureclick Etanercept Brand 11 $80,880
Otezla Apremilast Brand 13 $62,356
Eucrisa Crisaborole Brand 19 $17,900
Enstilar Calcipotriene/Betamethasone Brand 13 $17,825

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$524,772

Of which drugs: $122,131

Medicare patients

282

Average age 75

Services billed

7,092

135 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 33%
Ischemic heart disease 26%
Diabetes 25%
Chronic kidney disease 23%
Atrial fibrillation 18%
Heart failure 16%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 15 4,401 $5,847

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $395
  • Regeneron Healthcare Solutions, Inc. $249
$644 74 —
SKYRIZI
  • AbbVie, Inc. $423
$423 11 —
TREMFYA
  • Janssen Biotech, Inc. $380
$380 11 —
Bimzelx
  • UCB, Inc. $312
$312 — —
Otezla
  • Amgen Inc. $183
$183 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

747 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record